Charles Schwab Investment Management Inc. Acquires 7,165 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Charles Schwab Investment Management Inc. grew its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 1.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 604,397 shares of the biotechnology company's stock after purchasing an additional 7,165 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.95% of Blueprint Medicines worth $52,716,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BPMC. Quarry LP bought a new position in shares of Blueprint Medicines in the third quarter valued at approximately $32,000. R Squared Ltd bought a new position in Blueprint Medicines in the 4th quarter valued at $51,000. Covestor Ltd boosted its stake in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock valued at $55,000 after buying an additional 403 shares during the period. Asset Management One Co. Ltd. purchased a new position in Blueprint Medicines during the fourth quarter worth about $88,000. Finally, Van ECK Associates Corp increased its stake in Blueprint Medicines by 48.2% in the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $97,000 after acquiring an additional 363 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have commented on BPMC shares. Needham & Company LLC reissued a "buy" rating and issued a $133.00 price target on shares of Blueprint Medicines in a research note on Thursday, February 13th. StockNews.com cut Blueprint Medicines from a "hold" rating to a "sell" rating in a research note on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Wedbush reiterated an "outperform" rating and set a $128.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. boosted their target price on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $125.70.

Remove Ads

Blueprint Medicines Trading Up 2.9 %

Shares of BPMC stock traded up $2.56 during trading hours on Monday, reaching $92.14. The company's stock had a trading volume of 619,979 shares, compared to its average volume of 708,280. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a one year low of $80.68 and a one year high of $121.90. The stock has a market capitalization of $5.89 billion, a P/E ratio of -85.31 and a beta of 0.58. The firm's fifty day simple moving average is $99.54 and its 200 day simple moving average is $94.04.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities research analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $95.91, for a total transaction of $218,099.34. Following the transaction, the chief operating officer now owns 69,383 shares in the company, valued at approximately $6,654,523.53. This represents a 3.17 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ariel Hurley sold 2,250 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now directly owns 14,967 shares of the company's stock, valued at $1,496,700. This represents a 13.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,608 shares of company stock worth $4,668,161 over the last 90 days. 4.21% of the stock is owned by company insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.